Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NOVA: Guselkumab in moderate to severe hidradenitis suppurativa
NCT03628924Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2018
- Primary completion
- May 2020
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial of guselkumab in hidradenitis suppurativa (HS) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Hidradenitis Suppurativa Clinical Response at 16 weeks. Started Sep 2018; status: completed.
02
Drugs
guselkumab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT03628924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03628924.